Safety and immunogenicity of a novel multivalent OspA-based vaccine candidate against Lyme borreliosis: a randomised, phase 1 study in healthy adults Bézay et al.

https://www.thelancet.com/journals/laninf/home?dgcid=hubspot_email_jcr23_laninf&utm_campaign=jcr23&utm_medium=email&_hsmi=272117798&_hsenc=p2ANqtz-_5Ng__dMfcHZ76AywuGGbgURalKjX-w99-WeVHAKyksY2nP0jPvx9MNxcnIPtipvmSfasN31BYZddFIMbddvnLlfDF3A&utm_content=272117798&utm_source=hs_automation Oct 2023 Volume 23Number 10p1095-1206, e390-e454 Can we control dengue? The Lancet Infectious Diseases https://www.thelancet.com/journals/laninf/issue/current Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00299-2/fulltext?dgcid=hubspot_email_jcr23_laninf&utm_campaign=jcr23&utm_medium=email&_hsmi=272117798&_hsenc=p2ANqtz--Hq965Me3GzdYMCHrCO9aWMFTaubeMh-Zbx2bwMlqDdU9BTQ4XXVynY5tPymlna4AWjzJvtaYg899AwPtlgTHIqizlwA&utm_content=272117798&utm_source=hs_automation Clinical features and management of individuals admitted to hospital with monkeypox and associated complications across the UK: a retrospective cohort study Open Access https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00806-4/fulltext?dgcid=hubspot_email_jcr23_laninf&utm_campaign=jcr23&utm_medium=email&_hsmi=272117798&_hsenc=p2ANqtz-_zbHIafAX8N4A5k-vXWTLPYfhp6Ee4qm6jTMYJT69ucaihULbl9DFTIAa9UQiIWE6_oKFQfVcu-mm1QYHZ_4mLAaguAQ&utm_content=272117798&utm_source=hs_automation Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK) https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00184-6/fulltext?dgcid=hubspot_email_jcr23_laninf&utm_campaign=jcr23&utm_medium=email&_hsmi=272117798&_hsenc=p2ANqtz--ox9ZXXcdjaIRgYRl3us50Y1UFAf2V1cqvhFzWlIdYhk-GJFQtlfEES7fUTSXEecrp0oo3bl26HNCqoMdnA5WNqGz23w&utm_content=272117798&utm_source=hs_automation Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial Open Access https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00442-X/fulltext?dgcid=hubspot_email_jcr23_laninf&utm_campaign=jcr23&utm_medium=email&_hsmi=272117798&_hsenc=p2ANqtz--o9C5ShS9SgggreCu2NAZn7HJ7i_4PQXdc51H0VV3IhtA4TIo3DtqLEkLutLVkvtIm18yBB0c8qvDImUMnFz1y7xkjZQ&utm_content=272117798&utm_source=hs_automation Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00291-2/fulltext?dgcid=hubspot_email_jcr23_laninf&utm_campaign=jcr23&utm_medium=email&_hsmi=272117798&_hsenc=p2ANqtz-8hzvgopoVdXWZ4O9m5KkMJKSMpSoVCa2bbtwg6kd5ZdlAPG449JscN6BlpywM2SIqro5QOu1dLJgh3yrsap7ujtS7ifg&utm_content=272117798&utm_source=hs_automation